EGFR amplification and outcome in a randomised phase III trial of chemotherapy alone or chemotherapy plus panitumumab for advanced gastro-oesophageal cancers
Objective Epidermal growth factor receptor (EGFR) inhibition may be effective in biomarker-selected populations of advanced gastro-oesophageal adenocarcinoma (aGEA) patients. Here, we tested the association between outcome and EGFR copy number (CN) in pretreatment tissue and plasma cell-free DNA (cf...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
2021
|
| In: |
Gut
Year: 2021, Jahrgang: 70, Heft: 9, Pages: 1632-1641 |
| ISSN: | 1468-3288 |
| DOI: | 10.1136/gutjnl-2020-322658 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1136/gutjnl-2020-322658 Verlag, lizenzpflichtig, Volltext: https://gut.bmj.com/content/70/9/1632 
|
| Verfasserangaben: | Elizabeth C Smyth, Georgios Vlachogiannis, Somaieh Hedayat, Alice Harbery, Sanna Hulkki-Wilson, Massimiliano Salati, Kyriakos Kouvelakis, Javier Fernandez-Mateos, George D Cresswell, Elisa Fontana, Therese Seidlitz, Clare Peckitt, Jens C Hahne, Andrea Lampis, Ruwaida Begum, David Watkins, Sheela Rao, Naureen Starling, Tom Waddell, Alicia Okines, Tom Crosby, Was Mansoor, Jonathan Wadsley, Gary Middleton, Matteo Fassan, Andrew Wotherspoon, Chiara Braconi, Ian Chau, Igor Vivanco, Andrea Sottoriva, Daniel E Stange, David Cunningham, Nicola Valeri |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1799636755 | ||
| 003 | DE-627 | ||
| 005 | 20220820165452.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220414s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1136/gutjnl-2020-322658 |2 doi | |
| 035 | |a (DE-627)1799636755 | ||
| 035 | |a (DE-599)KXP1799636755 | ||
| 035 | |a (OCoLC)1341459036 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Smyth, Elizabeth C. |e VerfasserIn |0 (DE-588)1255405872 |0 (DE-627)1799639401 |4 aut | |
| 245 | 1 | 0 | |a EGFR amplification and outcome in a randomised phase III trial of chemotherapy alone or chemotherapy plus panitumumab for advanced gastro-oesophageal cancers |c Elizabeth C Smyth, Georgios Vlachogiannis, Somaieh Hedayat, Alice Harbery, Sanna Hulkki-Wilson, Massimiliano Salati, Kyriakos Kouvelakis, Javier Fernandez-Mateos, George D Cresswell, Elisa Fontana, Therese Seidlitz, Clare Peckitt, Jens C Hahne, Andrea Lampis, Ruwaida Begum, David Watkins, Sheela Rao, Naureen Starling, Tom Waddell, Alicia Okines, Tom Crosby, Was Mansoor, Jonathan Wadsley, Gary Middleton, Matteo Fassan, Andrew Wotherspoon, Chiara Braconi, Ian Chau, Igor Vivanco, Andrea Sottoriva, Daniel E Stange, David Cunningham, Nicola Valeri |
| 264 | 1 | |c 2021 | |
| 300 | |a 10 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a First online: 16 November 2020 | ||
| 500 | |a Gesehen am 14.04.2022 | ||
| 520 | |a Objective Epidermal growth factor receptor (EGFR) inhibition may be effective in biomarker-selected populations of advanced gastro-oesophageal adenocarcinoma (aGEA) patients. Here, we tested the association between outcome and EGFR copy number (CN) in pretreatment tissue and plasma cell-free DNA (cfDNA) of patients enrolled in a randomised first-line phase III clinical trial of chemotherapy or chemotherapy plus the anti-EGFR monoclonal antibody panitumumab in aGEA (NCT00824785). - Design EGFR CN by either fluorescence in situ hybridisation (n=114) or digital-droplet PCR in tissues (n=250) and plasma cfDNAs (n=354) was available for 474 (86%) patients in the intention-to-treat (ITT) population. Tissue and plasma low-pass whole-genome sequencing was used to screen for coamplifications in receptor tyrosine kinases. Interaction between chemotherapy and EGFR inhibitors was modelled in patient-derived organoids (PDOs) from aGEA patients. - Results EGFR amplification in cfDNA correlated with poor survival in the ITT population and similar trends were observed when the analysis was conducted in tissue and plasma by treatment arm. EGFR inhibition in combination with chemotherapy did not correlate with improved survival, even in patients with significant EGFR CN gains. Addition of anti-EGFR inhibitors to the chemotherapy agent epirubicin in PDOs, resulted in a paradoxical increase in viability and accelerated progression through the cell cycle, associated with p21 and cyclin B1 downregulation and cyclin E1 upregulation, selectively in organoids from EGFR-amplified aGEA. - Conclusion EGFR CN can be accurately measured in tissue and liquid biopsies and may be used for the selection of aGEA patients. EGFR inhibitors may antagonise the antitumour effect of anthracyclines with important implications for the design of future combinatorial trials. | ||
| 650 | 4 | |a gastric adenocarcinoma | |
| 650 | 4 | |a gastrointestinal cancer | |
| 650 | 4 | |a molecular oncology | |
| 650 | 4 | |a oesophageal cancer | |
| 700 | 1 | |a Vlachogiannis, Georgios |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hedayat, Somaieh |e VerfasserIn |4 aut | |
| 700 | 1 | |a Harbery, Alice |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hulkki-Wilson, Sanna |e VerfasserIn |4 aut | |
| 700 | 1 | |a Salati, Massimiliano |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kouvelakis, Kyriakos |e VerfasserIn |4 aut | |
| 700 | 1 | |a Fernandez-Mateos, Javier |e VerfasserIn |4 aut | |
| 700 | 1 | |a Cresswell, George D. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Fontana, Elisa |e VerfasserIn |4 aut | |
| 700 | 1 | |a Seidlitz, Therese |e VerfasserIn |4 aut | |
| 700 | 1 | |a Peckitt, Clare |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hahne, Jens C. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Lampis, Andrea |e VerfasserIn |4 aut | |
| 700 | 1 | |a Begum, Ruwaida |e VerfasserIn |4 aut | |
| 700 | 1 | |a Watkins, David |e VerfasserIn |4 aut | |
| 700 | 1 | |a Rao, Sheela |e VerfasserIn |4 aut | |
| 700 | 1 | |a Starling, Naureen |e VerfasserIn |4 aut | |
| 700 | 1 | |a Waddell, Tom |e VerfasserIn |4 aut | |
| 700 | 1 | |a Okines, Alicia |e VerfasserIn |4 aut | |
| 700 | 1 | |a Crosby, Tom |e VerfasserIn |4 aut | |
| 700 | 1 | |a Mansoor, Was |e VerfasserIn |4 aut | |
| 700 | 1 | |a Wadsley, Jonathan |e VerfasserIn |4 aut | |
| 700 | 1 | |a Middleton, Gary |e VerfasserIn |4 aut | |
| 700 | 1 | |a Fassan, Matteo |e VerfasserIn |4 aut | |
| 700 | 1 | |a Wotherspoon, Andrew |e VerfasserIn |4 aut | |
| 700 | 1 | |a Braconi, Chiara |e VerfasserIn |4 aut | |
| 700 | 1 | |a Chau, Ian |e VerfasserIn |4 aut | |
| 700 | 1 | |a Vivanco, Igor |e VerfasserIn |4 aut | |
| 700 | 1 | |a Sottoriva, Andrea |e VerfasserIn |4 aut | |
| 700 | 1 | |a Stange, Daniel Eduard |d 1980- |e VerfasserIn |0 (DE-588)133390446 |0 (DE-627)691400105 |0 (DE-576)276050142 |4 aut | |
| 700 | 1 | |a Cunningham, David |e VerfasserIn |4 aut | |
| 700 | 1 | |a Valeri, Nicola |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Gut |d London : BMJ Publishing Group, 1960 |g 70(2021), 9, Seite 1632-1641 |h Online-Ressource |w (DE-627)302725628 |w (DE-600)1492637-4 |w (DE-576)082435405 |x 1468-3288 |7 nnas |a EGFR amplification and outcome in a randomised phase III trial of chemotherapy alone or chemotherapy plus panitumumab for advanced gastro-oesophageal cancers |
| 773 | 1 | 8 | |g volume:70 |g year:2021 |g number:9 |g pages:1632-1641 |g extent:10 |a EGFR amplification and outcome in a randomised phase III trial of chemotherapy alone or chemotherapy plus panitumumab for advanced gastro-oesophageal cancers |
| 856 | 4 | 0 | |u https://doi.org/10.1136/gutjnl-2020-322658 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://gut.bmj.com/content/70/9/1632 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20220414 | ||
| 993 | |a Article | ||
| 994 | |a 2021 | ||
| 998 | |g 133390446 |a Stange, Daniel Eduard |m 133390446:Stange, Daniel Eduard |p 31 | ||
| 999 | |a KXP-PPN1799636755 |e 4117860194 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"person":[{"roleDisplay":"VerfasserIn","display":"Smyth, Elizabeth C.","role":"aut","family":"Smyth","given":"Elizabeth C."},{"family":"Vlachogiannis","given":"Georgios","display":"Vlachogiannis, Georgios","roleDisplay":"VerfasserIn","role":"aut"},{"family":"Hedayat","given":"Somaieh","display":"Hedayat, Somaieh","roleDisplay":"VerfasserIn","role":"aut"},{"role":"aut","display":"Harbery, Alice","roleDisplay":"VerfasserIn","given":"Alice","family":"Harbery"},{"given":"Sanna","family":"Hulkki-Wilson","role":"aut","display":"Hulkki-Wilson, Sanna","roleDisplay":"VerfasserIn"},{"given":"Massimiliano","family":"Salati","role":"aut","roleDisplay":"VerfasserIn","display":"Salati, Massimiliano"},{"display":"Kouvelakis, Kyriakos","roleDisplay":"VerfasserIn","role":"aut","family":"Kouvelakis","given":"Kyriakos"},{"given":"Javier","family":"Fernandez-Mateos","role":"aut","display":"Fernandez-Mateos, Javier","roleDisplay":"VerfasserIn"},{"given":"George D.","family":"Cresswell","role":"aut","roleDisplay":"VerfasserIn","display":"Cresswell, George D."},{"family":"Fontana","given":"Elisa","roleDisplay":"VerfasserIn","display":"Fontana, Elisa","role":"aut"},{"family":"Seidlitz","given":"Therese","roleDisplay":"VerfasserIn","display":"Seidlitz, Therese","role":"aut"},{"family":"Peckitt","given":"Clare","display":"Peckitt, Clare","roleDisplay":"VerfasserIn","role":"aut"},{"roleDisplay":"VerfasserIn","display":"Hahne, Jens C.","role":"aut","family":"Hahne","given":"Jens C."},{"given":"Andrea","family":"Lampis","role":"aut","display":"Lampis, Andrea","roleDisplay":"VerfasserIn"},{"roleDisplay":"VerfasserIn","display":"Begum, Ruwaida","role":"aut","family":"Begum","given":"Ruwaida"},{"role":"aut","roleDisplay":"VerfasserIn","display":"Watkins, David","given":"David","family":"Watkins"},{"display":"Rao, Sheela","roleDisplay":"VerfasserIn","role":"aut","family":"Rao","given":"Sheela"},{"roleDisplay":"VerfasserIn","display":"Starling, Naureen","role":"aut","family":"Starling","given":"Naureen"},{"display":"Waddell, Tom","roleDisplay":"VerfasserIn","role":"aut","family":"Waddell","given":"Tom"},{"given":"Alicia","family":"Okines","role":"aut","roleDisplay":"VerfasserIn","display":"Okines, Alicia"},{"given":"Tom","family":"Crosby","role":"aut","display":"Crosby, Tom","roleDisplay":"VerfasserIn"},{"display":"Mansoor, Was","roleDisplay":"VerfasserIn","role":"aut","family":"Mansoor","given":"Was"},{"given":"Jonathan","family":"Wadsley","role":"aut","display":"Wadsley, Jonathan","roleDisplay":"VerfasserIn"},{"given":"Gary","family":"Middleton","role":"aut","display":"Middleton, Gary","roleDisplay":"VerfasserIn"},{"roleDisplay":"VerfasserIn","display":"Fassan, Matteo","role":"aut","family":"Fassan","given":"Matteo"},{"family":"Wotherspoon","given":"Andrew","display":"Wotherspoon, Andrew","roleDisplay":"VerfasserIn","role":"aut"},{"roleDisplay":"VerfasserIn","display":"Braconi, Chiara","role":"aut","family":"Braconi","given":"Chiara"},{"roleDisplay":"VerfasserIn","display":"Chau, Ian","role":"aut","family":"Chau","given":"Ian"},{"given":"Igor","family":"Vivanco","role":"aut","roleDisplay":"VerfasserIn","display":"Vivanco, Igor"},{"given":"Andrea","family":"Sottoriva","role":"aut","display":"Sottoriva, Andrea","roleDisplay":"VerfasserIn"},{"role":"aut","display":"Stange, Daniel Eduard","roleDisplay":"VerfasserIn","given":"Daniel Eduard","family":"Stange"},{"given":"David","family":"Cunningham","role":"aut","roleDisplay":"VerfasserIn","display":"Cunningham, David"},{"role":"aut","roleDisplay":"VerfasserIn","display":"Valeri, Nicola","given":"Nicola","family":"Valeri"}],"title":[{"title_sort":"EGFR amplification and outcome in a randomised phase III trial of chemotherapy alone or chemotherapy plus panitumumab for advanced gastro-oesophageal cancers","title":"EGFR amplification and outcome in a randomised phase III trial of chemotherapy alone or chemotherapy plus panitumumab for advanced gastro-oesophageal cancers"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"note":["First online: 16 November 2020","Gesehen am 14.04.2022"],"recId":"1799636755","language":["eng"],"name":{"displayForm":["Elizabeth C Smyth, Georgios Vlachogiannis, Somaieh Hedayat, Alice Harbery, Sanna Hulkki-Wilson, Massimiliano Salati, Kyriakos Kouvelakis, Javier Fernandez-Mateos, George D Cresswell, Elisa Fontana, Therese Seidlitz, Clare Peckitt, Jens C Hahne, Andrea Lampis, Ruwaida Begum, David Watkins, Sheela Rao, Naureen Starling, Tom Waddell, Alicia Okines, Tom Crosby, Was Mansoor, Jonathan Wadsley, Gary Middleton, Matteo Fassan, Andrew Wotherspoon, Chiara Braconi, Ian Chau, Igor Vivanco, Andrea Sottoriva, Daniel E Stange, David Cunningham, Nicola Valeri"]},"origin":[{"dateIssuedDisp":"2021","dateIssuedKey":"2021"}],"id":{"doi":["10.1136/gutjnl-2020-322658"],"eki":["1799636755"]},"physDesc":[{"extent":"10 S."}],"relHost":[{"title":[{"title_sort":"Gut","subtitle":"an international journal of gastroenterology and hepatology","title":"Gut"}],"pubHistory":["1.1960 -"],"part":{"issue":"9","pages":"1632-1641","year":"2021","extent":"10","text":"70(2021), 9, Seite 1632-1641","volume":"70"},"titleAlt":[{"title":"Gut online"},{"title":"eGut"}],"type":{"media":"Online-Ressource","bibl":"periodical"},"disp":"EGFR amplification and outcome in a randomised phase III trial of chemotherapy alone or chemotherapy plus panitumumab for advanced gastro-oesophageal cancersGut","note":["Gesehen am 07.09.12"],"language":["eng"],"recId":"302725628","origin":[{"dateIssuedDisp":"1960-","publisher":"BMJ Publishing Group","dateIssuedKey":"1960","publisherPlace":"London"}],"id":{"eki":["302725628"],"zdb":["1492637-4"],"issn":["1468-3288"]},"physDesc":[{"extent":"Online-Ressource"}]}]} | ||
| SRT | |a SMYTHELIZAEGFRAMPLIF2021 | ||